<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739775</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2017-01 CIRCA-HPV</org_study_id>
    <nct_id>NCT03739775</nct_id>
  </id_info>
  <brief_title>Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses</brief_title>
  <acronym>CIRCA-HPV</acronym>
  <official_title>Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ctDNA detection in patients with previously treated, HPV-induced, stage II or III invasive&#xD;
      pelvic cancer and who are currently in post-treatment follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who&#xD;
      are currently in post-treatment follow-up will be included.&#xD;
&#xD;
      These patients will be followed up during 30 months (2.5 years) (if no relapse occurred&#xD;
      before) with ctDNA detection performed at each hospital visit. At each visit, clinical,&#xD;
      biological (squamous cell carcinoma (SCC) serum marker will be done systematically) and&#xD;
      radiological/pathology (if any) results will be prospectively collected in the study.&#xD;
&#xD;
      For the patients who have a relapse before 30 months, the follow-up will be discontinued at&#xD;
      the date of the relapse.&#xD;
&#xD;
      For the patients who will have completed their follow-up for the study (2.5 years) with no&#xD;
      relapse, they will be followed up for 6 months (+ 14 days), to collect any late relapse (if&#xD;
      any). None specific study procedure will be performed during this period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensibility of plasma circulating tumor DNA detection as a test to detect any (local or distant) relapse in patients who have been curatively treated for HPV-induced invasive pelvic cancer (cervix, anal canal, vagina, vulva, penis).</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Sensitivity= % of patients with detectable levels of ctDNA among those who experience a relapse within 6 months (+14 days) after the blood draw.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of plasma circulating tumor DNA detection as a test to detect any (local or distant) relapse in patients who have been curatively treated for HPV-induced invasive pelvic cancer (cervix, anal canal, vagina, vulva, penis).</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Specificity= % of patients with no detectable levels of ctDNA among those who don't experience a relapse within the 6 months after the blood draw (+14 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive predictive values of ctDNA.</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Positive Predictive Value= Probability of being diagnosed with a relapse within 6 months (+14 days) after positive testing (detection of ctDNA in the plasma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive values of ctDNA.</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Negative Predictive Value= Probability of being relapse-free during the 6 months (+14 days) after negative testing (no detection of ctDNA).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>HPV Positive Pelvic Cancer</condition>
  <arm_group>
    <arm_group_label>Blood sampling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.</description>
    <arm_group_label>Blood sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 1) Patient curatively treated within the past 3 years for:&#xD;
&#xD;
               -  a HPV-induced stage Ib3, Ic, II or III cervix cancer&#xD;
&#xD;
               -  a HPV-induced stage II or III anal canal, vagina, vulva or penis cancer&#xD;
&#xD;
          2. Patient with no evidence of any invasive tumor at inclusion (clinical and, if any,&#xD;
             radiological exams).&#xD;
&#xD;
          3. Age ≥ 18 years and &lt; 80 years.&#xD;
&#xD;
          4. Availability of HPV genotyping of the treated cancer and/or archived tumor tissue&#xD;
             available.&#xD;
&#xD;
          5. Patient who a follow-up visit is scheduled in the including center at least twice a&#xD;
             year.&#xD;
&#xD;
          6. Patient being affiliated to the French social security.&#xD;
&#xD;
          7. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient presenting with active invasive tumor masses (e.g. stage IV cancer).&#xD;
&#xD;
          2. Patient deprived from ability to decide on her own or placed under the authority of a&#xD;
             tutor.&#xD;
&#xD;
          3. Patient unable to have a regular follow up for geographical, social or psychological&#xD;
             reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François-Clément BIDARD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François-Clément BIDARD, PhD</last_name>
    <phone>+33 (0)1 47 11 18 80</phone>
    <email>francois-clement.bidard@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cyrine EZZILI</last_name>
    <phone>+33(0)1 47 11 16 57</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BORG, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe BORG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno BUECHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence HUGUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Astrid LIEVRE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Saint-Cloud</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roman ROUZIER, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV positive pelvic cancer</keyword>
  <keyword>Circulating tumor biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

